medigraphic.com
Colegio de Medicina Interna de México.

2013, Number 1

<< Back Next >>

Med Int Mex 2013; 29 (1)

Hypomagnesemia associated with proton pump inhibitors

Cantillano RSN, Casasola VJC, Rivera ZDJ

Language: Spanish
References: 23
Page: 62-66
PDF size: 155.99 Kb.


ABSTRACT

With the widespread use of proton pump inhibitors (PPIs) have appeared unexpected effects adverse. Recently there have been case reports of severe hypomagnesaemia associated with PPIs with producing of hypokalemia, hypocalcaemia and hypoparathyroidism leading to clinical manifestations endanger life of the patients. The cause of hypomagnesaemia seems to be an alteration in the intestinal absorption induced by prolonged use of PPIs. This is an unknown adverse effect by clinicians and therefore goes unnoticed as the cause of hypomagnesaemia. The diagnosis requires a high degree of clinical suspicion. It should monitor serum magnesium levels in patients treated which PPIs.


REFERENCES

  1. Forgacs I, Loganayagan A. Overprescribing proton pump inhibitors. BMJ 2008; 336: 2-3.

  2. Hollinworth S, Duncan EL, Martin JH. Marked increase in proton pump inhibitors use in Australia. Pharmacoepidemiol Drug Saf 2010.doi: 10. 1002/pds 1969.

  3. Epstein M, McGrath S, Law F. Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med 2006; 355: 1834-1836.

  4. Mackay JD, Bladon PT. Hypomagnesaemia due to protonpump inhibitor therapy: a clinical case series. QJM 2010; 103: 387-395.

  5. Shabajee N, Lamb EJ, Sturgess I, Sumathipala RW. Omeprazole and refractory hypomagnesaemia. BMJ 2008; 337: a425.

  6. Quamme GA. Recent developments in intestinal magnesium absorption. Curr Opin Gastroenterol 2008;24:230-235.

  7. Quamme GA, Schlingmann KP, Konrad M. Mechanisms and disorders of magnesium metabolism. In: Herbert SC, Alpern RJ, editors. The kidney: physiology and pathophysiology, 4th ed. San Diego: Elsevier, 2007;1747-1768.

  8. Sue DY, Bongard FS. Líquidos, electrólitos y equilibrio acido base. Editor, Morales Saavedra JL. Diagnóstico y tratamiento en cuidados intensivos. 3ª ed. México: Manual Moderno, 2009;51-54.

  9. Schlingmann KP, Waldegger S, Konrad M, et al. TRPM6 and TRPM7-gatekeepers of human magnesium metabolism. Biochim Biophys Acta 2007;1772: 813-821.

  10. Van Itallie CM, Anderson JM. Claudins and epithelial paracelular transport. Annu Rev Physiol 2006; 68: 403-429.

  11. Rose BD, Post TW. Asa de Henle y mecanismos contracorriente. Editores, Rose BD and Post TW. Trastornos de los electrolitos y del equilibrio acido base. 5ª ed. Madrid: Marban, 2005;112-116.

  12. Allgrave J, Adami S, Fraher L, Reuben A, O’ Riordan JL. Hypomagnesaemia: studies of parathyroid hormone secretion and function. Clin Endocrinol (Oxf) 1984;21:435-449.

  13. Rude RK, Oldham SB, Singer FR. Functional hypoparathyroidism and parathyroid hormone end-organ resistant in human magnesium deficiency. Clin Endocrinol (Oxf) 1976;5:209-224.

  14. Dimke H, Hoenderop JG, Bindels RJ. Hereditary tubular transport disorders: implications for renal handling of Ca 2+ and Mg 2+. Clin Sci (London) 2010;118:1-18.

  15. Weber T, Moreira GA. Hypomagnesaemia and proton pump inhibitors. Below the tip of the iceberg. Arch Inter Med 2011;35 112-117.

  16. Basterra-Gortari FJ, Goñi Iriarte MJ, García M, Iriarte Beroiz A. hipoparatiroidismo hipomagnesemico asintomático inducido por pantoprazol. Med Clin (Barc) 2011;137(11): 522-525.

  17. Cundy T, Dissanayake A. Severe hypomagnesaemia in longterm users of proton-pump inhibitors. Clin Endocrinol (Oxf) 2008; 69: 338-341

  18. Metz DC, Stosek MB, Ruszniewsky P. Effects of esomeprazole on acid output in patients with Zollinger-Ellison Syndrome or idiopathic gastric acid hypersecretion. Am J Gastroenterol 2007; 102: 2648-2654.

  19. François M, Levy-Bohbot N, Caron J, Durlach V. Chronic use of proton pump inhibitors: a rare cause of hypomagnesemic hypoparathyroidism? Ann Endocrinol (Paris) 2008; 69: 446- 448.

  20. Fernández - Fernández FJ, Sesma P, Cainzos-Romero T, Ferreira L. Hipomagnesemia asociada a tratamiento con omeprazol y test genético negativo para mutación en TRPM6. Med Clin (Barc). 2011; 137:188-191.

  21. Hoenderop JG, Bindels RJ. Calciotropic and magnesiotropic TRP channels. Physiology (Bethesda). 2008; 23:32-40.

  22. Mulin JM, Valenzano MC, Whitby M et al. Esomeprazole induces upper gastrointestinal tract transmucosal permeability increase. Aliment Pharmacol Ther 2008; 28:1317-1325.

  23. Kirchheiner J, Glatt S, Fuhr U, Klotz U, Meineke I, Seufferein T, et al. Relative potency of proton pump inhibitors-comparison of effects on intragastric PH. EUR J Clin Pharmacol 2009; 65: 19-31.




2020     |     www.medigraphic.com